Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more
Guizhou Sanli Pharmaceutical Co Ltd (603439) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.021x
Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has a cash flow conversion efficiency ratio of 0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.19 Million) by net assets (CN¥1.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guizhou Sanli Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guizhou Sanli Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Glass House Brands Inc
OTCQX:GLASF
|
-0.049x |
|
Acast AB
ST:ACAST
|
0.057x |
|
Alpha Networks Inc
TW:3380
|
0.008x |
|
Rockhopper Exploration plc
PINK:RCKHF
|
-0.003x |
|
De Rucci Healthy Sleep Co. Ltd.
SHE:001323
|
0.021x |
|
Beijing Sanfo Outdoor Products Co Ltd
SHE:002780
|
-0.032x |
|
Monalisa Group Co Ltd Class A
SHE:002918
|
0.075x |
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
N/A |
Annual Cash Flow Conversion Efficiency for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.59 Billion | CN¥107.07 Million | 0.067x | -58.52% |
| 2023-12-31 | CN¥1.71 Billion | CN¥276.70 Million | 0.162x | -31.66% |
| 2022-12-31 | CN¥1.24 Billion | CN¥293.29 Million | 0.237x | +57.68% |
| 2021-12-31 | CN¥1.03 Billion | CN¥155.04 Million | 0.150x | +133.21% |
| 2020-12-31 | CN¥981.88 Million | CN¥63.25 Million | 0.064x | -63.92% |
| 2019-12-31 | CN¥651.09 Million | CN¥116.24 Million | 0.179x | +22.74% |
| 2018-12-31 | CN¥518.02 Million | CN¥75.35 Million | 0.145x | +19.81% |
| 2017-12-31 | CN¥473.36 Million | CN¥57.47 Million | 0.121x | +48.93% |
| 2016-12-31 | CN¥430.59 Million | CN¥35.10 Million | 0.082x | -46.96% |
| 2015-12-31 | CN¥216.53 Million | CN¥33.28 Million | 0.154x | +2870.82% |
| 2014-12-31 | CN¥108.92 Million | CN¥563.46K | 0.005x | -98.81% |
| 2013-12-31 | CN¥69.09 Million | CN¥30.09 Million | 0.435x | -- |